Publication details
Přínos léčby bimekizumabem pro pacienty se závažnou psoriázou
| Title in English | Benefits of bimekizumab treatment for patients with severe psoriasis |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | NEČAS, Miroslav. Přínos léčby bimekizumabem pro pacienty se závažnou psoriázou (Benefits of bimekizumab treatment for patients with severe psoriasis). In Trýbův dermatologický den. 2024. |
| Description | Bimekizumab is a humanized monoclonal antibody that selectively inhibits interleukins IL17A and IL17F. Our experience with the treatment of psoriasis with bimekizumab is now almost two years and we currently have 14 patients on this therapy. All our patients are extremely satisfied with the treatment with bimekizmab. |